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Abstract
Minocycline normalizes synaptic connections and behavior in the knockout mouse model of 
fragile X syndrome (FXS). Human-targeted treatment trials with minocycline have shown benefits 
in behavioral measures and parent reports. Event-related potentials (ERPs) may provide a sensitive 
method of monitoring treatment response and changes in coordinated brain activity. Measurement 
of electrocortical changes due to minocycline was done in a double-blind, placebo-controlled 
crossover treatment trial in children with FXS. Children with FXS (Meanage 10.5 years) were 
randomized to minocycline or placebo treatment for 3 months then changed to the other treatment 
for 3 months. The minocycline dosage ranged from 25–100 mg daily, based on weight. Twelve 
individuals with FXS (eight male, four female) completed ERP studies using a passive auditory 
oddball paradigm. Current source density (CSD) and ERP analysis at baseline showed high-
amplitude, long-latency components over temporal regions. After 3 months of treatment with 
minocycline, the temporal N1 and P2 amplitudes were significantly reduced compared with 
placebo. There was a significant amplitude increase of the central P2 component on minocycline. 
Electrocortical habituation to auditory stimuli improved with minocycline treatment. Our study 
demonstrated improvements of the ERP in children with FXS treated with minocycline, and the 
potential feasibility and sensitivity of ERPs as a cognitive biomarker in FXS treatment trials.
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 Introduction
Fragile X syndrome (FXS) is the most common known inherited cause of intellectual 
disability and autism. It is a single-gene disorder (FMR1) with an expanded CGG 
trinucleotide repeat on the long arm of the X chromosome, Xq27.3. Fragile X Mental 
Retardation Protein (FMRP) is significantly diminished or absent in FXS through a 
methylation of a CpG island (Sutcliffe et al., 1992), silencing the FMR1 gene. Individuals 
with the FXS full mutation (>200 CGG repeats) show symptoms of hyperactivity, short 
attention span, emotional problems, and hyper-responsiveness to sensory stimuli (Schneider 
et al., 2009). Lack of FMR1 protein in FXS is considered to play a role in cortical 
hyperexcitability and abnormal synaptic transmission (Bear et al., 2004; Musumeci et al., 
2000). The neuropathological basis for this cortical excitation is thought to be the result of 
enhanced dendritic connections and immature pruning (Irwin et al., 2001). In addition, 
GABA A receptors are down regulated leading to deficits in inhibition and hyperarousal 
(D’Hulst and Kooy, 2007).
Minocycline normalizes synaptic connections and behavior in the knockout (KO) mouse 
model of FXS, which is thought to occur through decreasing levels or activity of MMP9 
(matrix metalloproteinase 9) (Bilousova et al. 2009). An open-label treatment trial and a 
retrospective review of minocycline treatment in FXS demonstrated significant benefits in 
behavior (Paribello et al., 2010; Utari et al., 2010).
However, most outcome measures in human trials are dependent on the feedback of 
caregivers and research staff assessments. The use of quantitative electroencephalography 
(EEG) and event-related potentials (ERPs) may provide an objective and sensitive method of 
monitoring changes in brain activity due to treatment.
EEG research in individuals FXS remains a challenging area, and only few studies have 
been published. Among the common findings are seizures (Berry-Kravis, 2002; Musumeci 
et al., 1999), abnormally large somatosensory evoked potentials (Ferri et al., 1995), and 
interictal paroxysmal EEG activity in prepubertal participants with FXS (Musumeci et al., 
1994). A magnet-encephalographic (MEG) study in FXS showed significantly higher 
amplitude N100m auditory evoked field component with a less lateralized N100m at 
anterior-posterior dipole locations (Rojas et al., 2001), which was explained by a more 
widespread activation of neurons in response to acoustic stimuli. Prepulse inhibition and 
recent ERP findings from Van der Molen et al. also provide neurophysiological evidence of 
enhanced sensitivity to auditory stimuli in FXS (Hessl et al., 2009; Van der Molen et al., 
2011b), which could be used as a biomarker in targeted treatment trials. Van der Molen and 
colleagues reported abnormal auditory information processing in FXS with enhanced N1, 
N2, and P2 components in a standard oddball task with auditory tones. A significant finding 
is the lack of habituation to repeated auditory stimuli, both in short-term and long-term 
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conditions in FXS, caused by a hypersensitive auditory feature detection system (Castren et 
al., 2003; Van der Molen et al., 2012).
Our EEG study is a pilot project on electrocortical changes in a subsample of children with 
FXS during a crossover trial with minocycline (Leigh et al., 2012). This larger clinical trial 
(Clinicaltrials.gov, http://www.clinicaltrials.gov/ct2/show/NCT01053156) was a 6-month, 
single center, placebo-controlled, double-blind crossover trial of minocycline treatment. In 
total, 55 participants received at least 3 months of either minocycline or placebo, and 48 
received 3 months of minocycline treatment and 3 months of placebo treatment. Medication 
dosage was assigned based on weight, with patients weighing up to 25 kg receiving 25 mg 
once daily, those weighing between 25 kg and 45 kg receiving 50 mg once daily, and those 
weighing >45 kg receiving 100 mg once daily. In this study, minocycline treatment was 
associated with improvements in global functioning by 0.5 points (CGI, Clinical Global 
Impression Scale) compared with placebo. On the Visual Analog Scale, the minocycline 
treatment was linked to a significant improvement in various behaviors, predominantly those 
related to anxiety and mood. No significant carry-over effects were observed from the first 
treatment period to the next.
 Methods and materials
The study was approved by the Institutional Review Board at University of California, 
Davis. All participants and parents/caretakers of participants gave their written consent to 
participate in the study.
 Participants
Out of the 55 individuals with FXS that participated in the controlled trial of minocycline, 
22 individuals participated in EEG recording first sessions. Twelve individuals successfully 
completed the EEG recordings (four females, eight males, Mean age 10.5 years, SD 3.7) at 
baseline, after 3 months of minocycline/placebo treatment, and again at 6 months, following 
the second arm of placebo or minocycline treatment (crossover trial). The reasons for drop-
outs were incomplete data for all three visits (N=5; two individuals discontinued the trial), 
data loss because of behavioral problems that interfered with the data quality (e.g. taking off 
the cap during the recording, hyperactivity, repetitive speech, N=4), and technical problems 
(N=1). The mean IQ in the sample was 64 (SD 23.7). There was a non-significant difference 
in IQ scores between the group that received the minocycline treatment first (see Table 1) 
that may have been clinically meaningful. Four individuals had mosaicism with partially 
methylated alleles in the premutation range in addition to a fully methylated full mutation. 
To compare the EEGs of the individuals with FXS in the minocycline trial, we included the 
results of a typically developing control group (N=40, Mean age 13.93 years, SD 10.58, 20 
males, 20 females, Mean IQ 106.6, SD 12.01) that was presented previously (Schneider et 
al., 2012, paper in preparation).
 Stimuli and procedure
Participants were presented with a passive auditory oddball paradigm using Presentation 
software (Neurobehavioral Systems, Albany, CA). The auditory stimuli were 350 sinusoidal 
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tones with frequencies of 1000 Hz (N=315, standard tone), and 2000 Hz (N=35, target/
oddball), generated with the Tone Generator software of NCH (http://nch.com.au). The tones 
had a 10 ms rise/fall, 50 ms plateau, and a sound pressure intensity of 70 dB. The 
randomized order consisted of first six 1000 Hz standard tones, then one target tone (2000 
Hz) either at 7th, 8th, 9th, or 10th position, with standard tones presented in the remaining 
positions. The tones were presented with a consistent inter-stimulus interval (ISI) of 1000 
ms over stereo-speakers. At the beginning of the experiment, the sound intensity at the 
participant’s head location was confirmed with a digital sound level meter.
Before the experiment, the participants chose a favorite movie, which was shown without 
sound during the preparation and the oddball task. The movie was required in order to 
provide a comforting environment for the patients and provide a fixation point for their eyes 
to reduce eye and head movements. Before the experiment, 2 min of resting EEG was 
recorded and, in compliant participants, an Alpha-block paradigm was completed with four 
30-s blocks of alternating eyes-open and eyes-closed continuous EEG recording. Also, 
positive reinforcement through stickers and a reward sheet was utilized to encourage 
compliance.
 EEG acquisition
EEG data were acquired using a Brain Products Quickamp system with an Acticap 32-
channel Ag+/Ag+Cl− active EEG electrode array (International 10–20 system, positions 
(Fp1, Fp2, F7, F3, Fz, F4, F8, FC5, FC1, FC2, FC6, T7, C3, Cz, C4, T8, TP9, CP5, CP1, 
CP2, CP6, TP10, P7, P3, Pz, P4, P8, PO9, O1, Oz, O2, PO10)) using a common average 
reference and a ground electrode positioned between Fz and Pz sites. Electrode impedances 
were maintained below 10 kΩ and electrical activities amplified and recorded with Brain 
Vision Recorder and Quickamp amplifier (Brain Products, Germany). During the recording, 
bandpass filters set at 0.3–100 Hz, and data were digitized continuously at 250 Hz. Raw data 
were then imported into Brainvision Analyzer software (Version 2.0.1.558, Brainproducts) 
for analysis.
 Data processing
The continuous data were segmented according to the event type (standard or target tone 
with a 1000 ms time window, −100 ms before the event until 900 ms after the event) and 
filtered (Butterworth Zero Phase Filters with low cutoff 0.5 Hz, time constant 0.3, 12 dB/oct, 
high cutoff: 40 Hz, 12 dB/oct, a notch filter was not applied because of the active shield 
technology).
For artifact rejection, we defined the maximal allowed voltage step in a segment to 50 
μV/ms, with a maximal allowed difference of values in intervals of 1000 μV, minimal 
allowed amplitude −500 μV, maximal allowed amplitude 500 μV, minimum activity in 
intervals 0.5 μV. For the detection and correction of blinks we used the electrode sites Fp1 
and Fp2 as source for an Independent Component Analysis (ICA) Infomax restricted slope 
algorithm. The components relevant for vertical activity were selected by computing the 
global power field power. The number of ICA steps and convergence bound were selected 
individually according to the quality of the data; in general, the ocular correction ICA 
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converged between 90–120 steps, with the last step’s matrix modification usually smaller 
than 9.575E-08. In general, there was a loss of ~10% of all trials. We excluded participants 
without a sufficient number of artifact-free trials (>30 required for oddball tones, >200 for 
standard tones).
 Event-related potentials
ERPs were baseline corrected using the 100 ms pre-stimulus interval and averaged for 
standards and target tones separately. Peak amplitude and latency of the N1, P2, and N2 
components were determined at the Fz, F3, F4, Cz, C3, C4, Pz, P3, P4, T7, and T8 electrode 
positions by the largest voltage deflection within the 1000 ms time window relative to 
stimulus onset, depending on the specific latency range for each component (N1=80–140 
ms, P2=120–200 ms, N2=200–350 ms) according to established ERP guidelines (Duncan et 
al., 2009; Picton et al., 2000). The peak detection was performed semi-automatically, and a 
large voltage deflection also determined as a peak manually after visual inspection if it was 
outside the pre-defined latency range.
 Source localization
 Current source density—The current source density (CSD) is a measure of cortical 
activity that replaces the voltage values at electrodes that have valid head coordinates with 
the current source density at these points. The averaged ERP waveforms were transformed 
into CSD estimates (μV/m2units) using a spherical spline surface Laplacian method (order 
of splines: 4, maximal degree of Legendre polynominals: 10, approximation parameter 
lambda: 1.00e-005), based on the method by Perrin and colleagues (Perrin et al., 1989; 
Tenke and Kayser, 2012).
 Statistical analysis
For the analysis, we only included the standard tone stimulus because the number of artifact-
free trials of the non-standard tones was too limited (N<30 for most participants). Due to the 
small sample sizes, and non-normal data distributions, our analyses were restricted to non-
parametric comparisons between baseline and minocycline conditions (collapsed across both 
the minocycline and placebo treatment arms) and between baseline and placebo conditions 
(also collapsed across arms).
Statistical analysis of the ERP/CSD data was performed with a non-parametric Friedman 
Rank Test, Bonferroni correction, and post-hoc Wilcoxon procedure for condition 
comparison: baseline to minocycline condition, baseline to placebo condition, and placebo 
to minocycline condition. For the analysis of habituation to the tone stimuli we analyzed the 
N1/P2 waveforms to the first 45 tones, compared with the last 45 tones (Van der Molen et 
al., 2012). We also performed an exploratory analysis to test the hypothesis that larger P2 
amplitude at Cz (where the P2 is normally maximal) in association with minocycline 
treatment would correlate (using Spearman’s rho) with global clinical improvement, i.e. 
higher CGI (Guy, 1976) scores. As this was a directional hypothesis, a one-tailed p-value of 
≤0.05 was considered significant.
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Figure 1 shows the grand average surface potentials (ERP) for the standard tones at baseline, 
placebo, and minocycline conditions for electrode positions Cz, T7, and T8. We selected 
these electrode positions in the figure because they most reliably showed the ERP 
components of interest across all participants. The P2 component at the Cz electrode shows 
a significant difference between baseline, placebo, and minocycline, with the highest 
amplitude for the minocycline treatment (z=−2.66, p .008). The N1 amplitude shows a 
similar trend at the Cz electrode, but it is not statistically significant (z=.549, p .583). The 
temporal waveforms at T7 and T8 show significantly reduced amplitudes for N1 on 
minocycline treatment compared with baseline (T7 and T8) or placebo (T8). The P2 
amplitude was also increased at T8 on minocycline treatment compared with baseline/
placebo (P2T8, z=−2., p .041). There were no significant differences in peak latencies. 
Compared with typically developing controls, the N1 component at T7 and T8 of the 
minocycline FXS group shows comparable amplitudes, the N1 and P2 amplitudes at the Cz 
electrode location are significantly higher than controls.
Table 2 gives an overview of the mean amplitudes, standard deviations (SD), and statistical 
comparisons of N1, P2, and N2 at electrode positions Cz, T7, and T8. Our exploratory 
correlational analysis found that an increase in the P200_amplitude at Cz (from baseline to 
minocycline treatment) was correlated with CGI improvement in the expected direction (rho 
= .54, one-tailed p = 0.045).
Table 3 gives an overview of the mean amplitudes, SDs, and statistical analyses of N1, P2, 
and N2 at electrode positions Cz, T7, and T8 of a typical developing control group in 
comparison to the minocycline treatment FXS group.
Figure 2 shows the surface Laplacian topography (CSD) maps in 50 ms steps from 50–200 
ms after stimulus presentation. There is a similar bi-temporal negative activation pattern in 
both hemispheres at baseline and placebo condition (between 150–250 ms). With 
minocycline treatment, the temporal negative activation pattern is counterbalanced with a 
strong central positive activation pattern (increased P2 amplitude at Cz). These CSD maps 
following minocycline treatment resemble the cortical activation patterns of typical 
developing individuals (Schneider et al., 2012).
For the analysis of habituation to repeated stimuli (Van der Molen et al., 2012), we 
compared the ERP waveforms for the first 45 stimuli to the last 45 stimuli, dependent on 
baseline, placebo, or minocycline conditions. Figure 3 shows the grand average waveforms, 
Figure 3(a) the N1 amplitude attenuation, and Figure 3(b) the P2 attenuation.
The N1 amplitude at baseline condition for the first vs. last 45 tones does not show a change 
in amplitude (CzN1_first45=−1.568, CzN1_last45=−1.6584, mean difference 0.090 μV), the P2 
component shows a tendency for a reduced amplitude, but this is not statistically significant 
(CzP2_first45=2.670, CzP2_last45=2.145, mean difference 0.524 μV). The placebo condition 
comparisons show a similar pattern (CzN1_first45=−3.302, CzN1_last45=−4.061, mean 
difference 0.75 μV), and the P2 component (CzP2_first45=5.011, CzP2_last45=5.697, mean 
difference −0.686 μV), both not statistically significant. For the minocycline treatment 
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condition, there were significant amplitude reductions in both the N1 and P2 components 
(CzN1_first45=−5.857, CzN1_last45=−3.336, mean difference −2.520 μV, z=−2.72, p .002, and 
CzP2_first45=7.370, CzP2_last45=5.185, mean difference −2.185 μV, z=−2.63, p .012).
 Discussion
This is the first study to examine electrocortical changes in the context of a controlled 
targeted treatment trial in FXS. We tested the hypothesis that a simple, auditory ERP 
paradigm would be sensitive to changes in cortical activation patterns during auditory 
information processing (0–400 ms) associated with minocycline treatment. In the 2009 
Bilosouva study (Bilousova et al., 2009), minocycline reversed the abnormal behaviors in 
Fmr1 KO mice, and promoted dendritic spine maturation in vivo and in vitro. One of 
potentially important EEG findings in our present study is the attenuation of the temporal N1 
waveform, which could be an indicator of a reduced auditory hyperexcitability with 
minocycline. One plausible mechanism might be that dendritic spines become more mature 
with minocycline treatment, as shown in the KO mouse model (Bilousova et al. 2009). In 
previous studies, individuals with FXS showed exaggerated N1 and P2 amplitudes to 
auditory stimuli (Van der Molen et al., 2011a), providing evidence for this auditory 
hypersensitivity, which may be normalized by lowered MMP9 activity associated with 
minocycline treatment. Reduction or absence of FMRP is known to play a role in producing 
cortical hyperexcitability and abnormal synaptic transmission (Chuang et al., 2005; Zhong et 
al., 2009) The neurobiological basis for the hyperexcitability is thought to be related to 
GABA and glutamate imbalances and synaptic plasticity deficits, leading to deficits in 
dendritic connections.
The increase of ERP amplitudes at the central electrode position during the minocycline 
treatment appears counterintuitive; if minocycline reduces cortical hyperexcitability, the 
central amplitudes should be decreased. One possibility for the increased P2 at Cz is a 
summation of dipoles with temporal negative and midline positive peaks. Another possible 
explanation is the comparison of ERPs elicited by the first 45 standard tones in comparison 
with the last 45 standard tones, which provides insight into the habituation to stimulus 
presentation. Participants demonstrated significant ERP amplitude habituation to auditory 
stimuli only following minocycline treatment, comparable with healthy controls in a prior 
study (Van der Molen et al., 2012). It is known that enhancements in central processing are 
associated with improvements in habituation and the enhanced CZ amplitude may relate to 
this improvement in habituation. A final potential interpretation of the increased P2 is that 
minocycline exaggerates rather than ameliorates the electrocortical phenotype. However, our 
preliminary correlational analyses found an association between larger central P2 amplitude 
and improved global clinical outcome (CGI scores). Clearly, larger sample sizes and 
independent replication would help to clarify the reliability and nature of this observation.
Study limitations include the small sample size and the behavioral difficulties with lower-
functioning, non-verbal participants resulting in EEG data loss due to excessive movement 
and other artifacts. For example, we only included the response to the standard tone stimulus 
in the analysis because the number of artifact-free trials of the non-standard tones was too 
limited (N<30 for most participants). However, including the non-standard tones (perhaps by 
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increasing the proportion of such trials or reducing factors contributing to artifacts) would 
add further insights into cortical processing, for example into the mismatch negativity 
(MMN) component, believed to be an indicator of early sensory change detection and 
sensory memory (Naatanen et al., 2011). A study by Van der Molen (2011a) found a 
significantly reduced MMN in FXS males relative to controls in a passive auditory odd-ball 
paradigm. The small sample size and non-normal distribution of data also prevented us from 
using standard parametric analyses that would allow for robust examination of treatment 
effects and carry-over. However, we performed an effect size analysis, depending on the 
treatment order, minocycline on the first arm vs. placebo on the first arm before the 
crossover (supplemental analysis). The general finding shows a bigger effect size for the 
group that started with minocycline on the first treatment arm. This modest order effect is 
most likely a cohort effect, in which the subjects randomized to minocycline on the first arm 
were in some way different (perhaps related to level of functioning) and more responsive 
than the second group. Also, our study sample included male and female participants. 
Generally, the phenotype in female individuals with FXS is milder, with a higher IQ and 
higher adaptive functioning, and it can be expected that the electrocortical patterns differ 
significantly. However, to our knowledge there have been no ERP studies on gender 
differences in FXS, and our study sample is too small to compare the effects.
Also, the different molecular status of four participants with methylation mosaicism adds to 
the data heterogeneity. The limited sample size prevents clear comparison of these 
individuals; however, differential treatment response to an mGluR5 negative modulator 
associated with differences in methylation has been reported (Jacquemont et al., 2011). We 
are not aware of any other EEG studies in FXS that looked at differences between cortical 
activation patterns in individuals with partially and fully methylated alleles. The treatment 
period of only 3 months could be too short for the minocycline to reach full effect, 
especially in adolescents. There was no formal wash-out period in the design of the study 
and carry-over effects may be possible. However, the analysis of the original sample in the 
larger minocycline study did not show a statistically significant carry-over effect on clinical 
outcome measures collected 14 days after stopping treatment (Leigh et al., 2012).
In the present study, we showed the potential sensitivity of an EEG biomarker as an 
indicator of cortical changes in FXS in a targeted treatment trial. It provides a measure for 
the human equivalent of the cortical hyperexcitability demonstrated in the mouse model of 
FXS. ERP/EEG studies can provide important additional treatment outcome measures and 
their use is recommended in future targeted treatment trials for FXS.
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(a) Grand averaged waveforms to standard tone at electrode positions T7 (left), Cz (center), 
and T8 (right) at baseline, placebo and minocycline conditions. Negative is plotted upwards. 
(b) Amplitudes for N1, P2, and N2 components; patients demonstrated a significant 
reduction of N1 amplitudes at T7 and T8 on minocycline compared with baseline, increased 
P2 amplitude at Cz and T8, and an increased N2 amplitude at Cz. (c) Grand averaged 
waveforms to standard tone at electrode positions T7 (left), Cz (center), and T8 (right), 
comparison of the minocycline group with a control sample. (d) Amplitudes for N1, P2, and 
N2 components; individuals with FXS on minocycline compared with controls show similar 
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N1 amplitudes at T7 and T8, a significant higher N1 component at Cz, and a larger P2 
amplitude at T7 and Cz.
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Current Source Density group grand average maps for 200 ms after stimulus presentation, 
top view from scalp, nose on top. Arrows indicate differences in activation patterns for the 
different conditions.
(1) reduced early left-temporal component (N1 equivalent) from baseline to minocycline 
condition, similar to controls (2) reduced temporal negative components in both 
hemispheres, a finding that is absent in controls (3) increased central positive component (P2 
equivalent at Cz), which is absent in controls.
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(a) Grand average waveforms at Cz, highlighted in yellow the N1 component, the P2 
component in blue. Black line signifies first 45 stimuli, the red line last 45 stimuli potentials. 
Negative plotted upwards. (b) Significantly improved attenuation of N1 and P2 in 
minocycline condition, not significant for baseline and placebo.
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Table 3
Group differences in ERP amplitudes (t-test).
ERP (μV)/Electrode position Controla (N=40) Minocycline (N=12) (t, Sig.)
N1_Cz −1.44 −4.20 3.06
(SD 2.43) (SD 3.58) .003
N1_T7 −0.23 −0.19 0.090
(SD 1.32) (SD 1.49) .927
N1_T8 −1.02 0.46 1.79
(SD 2.68) (SD 1.80) .079
P2_Cz 3.74 7.68 4.58
(SD 2.60) (SD 2.60) .000
P2_T7 0.70 3.87 8.11
(SD 1.23) (SD 1.00) .000
P2_T8 3.65 3.24 0.32
(SD 4.22) (SD 2.23) .745
N2_Cz −2.34 −2.09 0.52
(SD 1.57) (SD 1.00) .604
N2_T7 −5.12 −4.08 0.82
(SD 4.32) (SD .90) .413
N2_T8 −5.32 −4.41 0.85
(SD 3.65) (SD .96) .397
a
Control group: N=40, Mean age 13.93 (SD 10.58), Mean IQ 106.6 (SD 12.01)
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